Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O14662
UPID:
STX16_HUMAN
Alternative names:
-
Alternative UPACC:
O14662; A6NK32; A6NN69; A8MPP0; B7ZBN1; B7ZBN2; B7ZBN3; E1P5M0; E1P607; O14661; O14663; O60517; Q5W084; Q5W086; Q5W087; Q5XKI6; Q6GMS8; Q9H0Z0; Q9H1T7; Q9H1T8; Q9UIX5
Background:
Syntaxin-16, a SNARE protein, plays a crucial role in vesicular transport from the late endosomes to the trans-Golgi network. Its precise function and structure are key to understanding intracellular trafficking processes.
Therapeutic significance:
The involvement of Syntaxin-16 in Pseudohypoparathyroidism 1B, a disorder marked by resistance to parathyroid hormone, highlights its potential as a therapeutic target. Understanding the role of Syntaxin-16 could open doors to potential therapeutic strategies.